<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04069156</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10305</org_study_id>
    <nct_id>NCT04069156</nct_id>
  </id_info>
  <brief_title>The ARIES HeartMate 3 Pump IDE Study</brief_title>
  <official_title>Antiplatelet Removal and HemocompatIbility EventS With the HeartMate 3 Pump IDE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, double-blinded, placebo-controlled clinical investigation of
      advanced heart failure patients treated with the HM3 with two different antithrombotic
      regimens: vitamin K antagonist with aspirin versus vitamin K antagonist with placebo
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical investigation is a prospective, randomized, double-blinded, placebo-controlled
      study of advanced heart failure patients treated with the HM3 with two different
      antithrombotic regimens: vitamin K antagonist with aspirin versus vitamin K antagonist with
      placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blinded, randomized 1:1, active arm versus placebo arm</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Investigator, site, patient, CEC, and core lab are blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Non-inferority Primary Endpoint</measure>
    <time_frame>1 year post implant</time_frame>
    <description>The primary endpoint for this study will be met if the placebo arm is non-inferior to the aspirin arm in the composite of survival free of any non-surgical (any event occuring &gt; 14 days post implant) major hemocompatibility related adverse event (Stroke, pump thrombosis, bleeding [intracranial bleeds that do not meet stroke definition], arterial peripheral thromboembolism), at 1-year post implant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-Surgical Bleeding Secondary Endpoint</measure>
    <time_frame>Up to 3 years post implant</time_frame>
    <description>The non-surgical bleeding rate per patient year will be compared between treatment groups in the Primary Endpoint Population using Poisson regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antiplatelet Therapy Removal Safety Endpoint</measure>
    <time_frame>Up to 3 years post implant</time_frame>
    <description>To assess the safety of removal of antiplatelet therapy from the antithrombotic regimen between the two arms of the study using all patient follow up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">628</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LVAD Patients on the placebo arm will be given placebo medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LVAD Patients on the active arm will be given 100mg Aspirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LVAD Implant</intervention_name>
    <description>Subjects will undergo Heartmate 3 LVAD implant prior to randomization</description>
    <arm_group_label>Active Arm</arm_group_label>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 100mg</intervention_name>
    <description>Subjects will be randomized to either Placebo or Aspirin post implant.</description>
    <arm_group_label>Active Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Subjects will be randomized to either Placebo or Aspirin post implant</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject will receive the HeartMate 3 per standard of care (SOC) in accordance with the
             approved indications for use in the country of implant.

          2. Subject will receive the HeartMate 3 as their first durable VAD.

          3. Subject must provide written informed consent prior to any clinical investigation
             related procedure.

          4. In female patients of child bearing capability, subject will not be currently pregnant
             or breastfeeding and on appropriate contraception.

        Exclusion Criteria:

          1. Post-implant additional temporary or permanent mechanical circulatory support (MCS).

          2. Investigator mandated antiplatelet therapy for other conditions (including mandated
             presence or absence of antiplatelet agent).

          3. Patients who are nil per os (NPO) post-implant through day 7.

          4. Subjects with a known allergy to acetylsalicylic acid (aspirin).

          5. Participation in any other clinical investigation(s) involving an MCS device, or
             interventional investigation(s) likely to confound study results or affect study
             outcome.

          6. Presence of other anatomic or comorbid conditions, or other medical, social, or
             psychological conditions that, in the investigator's opinion, could limit the
             subject's ability to participate in the clinical investigation or to comply with
             follow-up requirements, or impact the scientific soundness of the clinical
             investigation results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Poornima Sood, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Program Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nina Sinanovic</last_name>
    <phone>4084257259</phone>
    <email>nina.sinanovic@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Crandall, PhD</last_name>
    <phone>7815528016</phone>
    <email>daniel.crandall5@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sharp Memorial Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Adamson, MD</last_name>
      <phone>858-939-7471</phone>
      <email>rmadamsonmd@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Chris Kohlmyer</last_name>
      <phone>(858) 244-6886</phone>
      <email>ckohlmyer@sdcardiac.com</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Adamson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Jaski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center - Van Ness Campus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brett Sheridan, MD</last_name>
      <phone>415-600-5780</phone>
      <email>sheridbc@PAMF.org</email>
    </contact>
    <contact_backup>
      <last_name>Milena Ferreira</last_name>
      <phone>(415) 600-5707</phone>
      <email>ferreiml@sutterhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ranjan Ray, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Pham, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jared Herr, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu Xie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York-Presbyterian/Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nir Uriel, MD</last_name>
      <phone>212-342-1327</phone>
      <email>nu2126@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dawn Scotto</last_name>
      <phone>(212) 305-1368</phone>
      <email>des2164@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nir Uriel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriel Sayer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yoshifumi Naka, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Koji Takeda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paolo Colombo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Veli Topkara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melana Yuzefpolskaya, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 21, 2019</study_first_submitted>
  <study_first_submitted_qc>August 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>ventricular assist device</keyword>
  <keyword>LVAD</keyword>
  <keyword>aspirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>To be determined</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

